novartis ag deal is set for rights to antismoking vaccine novartis ag will buy global rights to an antismoking vaccine made by switzerlands cytos biotechnology ag in a deal valued at as much as million swiss francs &# million the sale will take place even though the drug failed to meet primary endpoints in a phase ii trial last year the deal reflects the growing pace of biotech product acquisitions by big pharmaceutical companies 
